| 1 |
33611805 | Anlotinib, Vincristine, and Irinotecan for Advanced Ewing Sarcoma After Failure of Standard Multimodal Therapy: A Two-Cohort, Phase Ib/II Trial. | 2021 Jul |
2 |
| 2 |
34303840 | A targeted combinatorial therapy for Ewing's sarcoma. | 2021 Oct |
1 |
| 3 |
34941047 | Quality of life and Q-TWiST were not adversely affected in Ewing sarcoma patients treated with combined anlotinib, irinotecan, and vincristine: (Peking University People's Hospital Ewing sarcoma trial-02, PKUPH-EWS-02). | 2021 Dec 23 |
2 |
| 4 |
28974650 | Inhibition of the oncogenic fusion protein EWS-FLI1 causes G2-M cell cycle arrest and enhanced vincristine sensitivity in Ewing's sarcoma. | 2017 Oct 3 |
4 |
| 5 |
25662499 | Plasma hydrogenated cationic detonation nanodiamonds efficiently deliver to human cells in culture functional siRNA targeting the Ewing sarcoma junction oncogene. | 2015 Mar |
1 |
| 6 |
23497288 | miR-125b develops chemoresistance in Ewing sarcoma/primitive neuroectodermal tumor. | 2013 Mar 4 |
1 |
| 7 |
21960059 | miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy. | 2012 Apr |
1 |